EntreMed of Rockville gets Nasdaq warning

Daily Record, The (Baltimore), Apr 8, 2008

EntreMed Inc., of Rockville, a biopharmaceutical company developing therapeutics for the treatment of cancer and inflammation, said it received a warning from Nasdaq that its common stock is subject to being delisted due to failing to close above the minimum closing bid price of $1 per share for 30 consecutive business days.

To achieve compliance, the stock must meet or exceed the minimum share price for 10 consecutive business days. EntreMed has until Oct. 1 to comply. It said it is considering a reverse stock split among other alternatives. EntreMed's stock closed on Monday at 73 cents, down a penny.

Copyright 2008 Dolan Media Newswires
Provided by ProQuest Information and Learning Company. All rights Reserved.

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with ProQuest